Detail of "137348-86-8"

Reference

Glycogen synthase kinase-3 inhibitors

Glycogen synthase kinase-3 inhibitors. Eldar-Finkelman, Hagit (Tel Aviv University Future Technology Development L.P., Israel). PCT Int. Appl. WO 2005000192 A2 6 Jan 2005, 134 pp.There are some reagents with their cas registry numbers 200809-09-2 and 137348-86-8 are used in this study. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K. APPLICATION: WO 2004-IL570 27 Jun 2004. PRIORITY: US 2003-2003/PV48271U 27 Jun 2003; US 2003-2003/PV528495 11 Dec 2003. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 7, 25, 27 The present invention relates to novel compds. for inhibiting glycogen synthase kinase-3 (GSK-3) and their use in regulating biol. conditions mediated by GSK-3 activity and, more particularly, to the use of these compds. in the treatment of biol. conditions such as type II diabetes, neurodegenerative disorders and diseases and affective disorders. .